Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of...

Area of Science:

• Oncology
• Pharmacology
• Bone Metastasis Research

Background:

• Renal cell carcinoma (RCC) frequently metastasizes to bone, leading to significant morbidity.
• Established bone metastases present a therapeutic challenge, necessitating novel treatment strategies.
• Understanding the mechanisms of bone metastasis is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the efficacy of YM529, a third-generation bisphosphonate, in inhibiting established bone RCC progression.
• To elucidate the mechanisms by which YM529 and interferon-alpha (IFN-α) affect RCC and bone cells.
• To evaluate the potential of combined YM529 and IFN-α therapy for human RCC bone metastasis.

Main Methods:

• In vitro studies assessed antiproliferative and apoptosis-inducing effects on RCC cells and osteoclasts using cell counting.
• In vivo studies utilized nude mice bearing human RCC xenografts, treated with YM529 and/or IFN-α.
• Assays included soft X-ray, TUNEL, tartrate-resistant acid phosphatase staining, pit formation, micro-vessel density, and in situ mRNA hybridization.

Main Results:

• YM529 significantly decreased osteoclast numbers in bone tumors and inhibited osteoclast activity and proliferation in vitro.
• IFN-α reduced basic fibroblast growth factor expression and micro-vessel density within tumors, indicating antiangiogenic effects.
• Neither YM529 nor IFN-α alone demonstrated significant inhibition of established bone metastatic tumor growth.

Conclusions:

• Combined treatment with YM529 and IFN-α shows potential benefit for patients with human RCC bone metastasis.
• YM529 exerts its effects by inhibiting osteoclast recruitment and activity.
• IFN-α contributes to therapeutic efficacy through its antiangiogenic properties.